CJC-1295/ipamorelin or IGF-1 LR3?
Different points in a signaling pathway do not create a proven beginner-to-advanced treatment ladder.
The short answer
The sources here do not establish a direct clinical comparison for muscle growth or recovery. CJC-1295 hormone-marker results and laboratory IGF-1 analogue research cannot rank these compounded products by benefit.
IGF-1 LR3 is not currently offered through AnthologyRX. This comparison remains available for general information.
Side by side
| CJC-1295/ipamorelin | IGF-1 LR3 | |
|---|---|---|
| Approach | A blend acting on growth-hormone release | A modified IGF-1 analogue |
| Cited evidence | Individual-ingredient research | Laboratory analogue research |
| Unproven inference | Hormone increases guarantee recovery benefits | Direct signaling makes it a better escalation |
What the evidence shows
The CJC-1295 studies used a long-acting single ingredient and measured hormone responses. The LR3-related paper studied analogue behavior in laboratory systems. Neither is a head-to-head patient trial of the products compared here.
Read: Teichman et al. Long-acting CJC-1295 in healthy adults; Beck et al. IV ipamorelin after bowel surgery; Francis et al. IGF-1 analogues and binding proteins; FDA: Compounding questions and answers.
What matters for your decision
Ask what specific condition is being treated and what human evidence supports that use. Do not escalate from one to another because a marker changed less than expected or a product is marketed as stronger. Monitoring and a clear treatment rationale matter for either proposal.
Questions
Is IGF-1 LR3 simply prescription IGF-1?
The exact analogue matters. Evidence or approval for a different IGF-1 preparation cannot establish the safety and effectiveness of LR3.
Sources
- Teichman et al. Long-acting CJC-1295 in healthy adults
JCEM, 2006. Short studies of GH and IGF-1 responses; not a trial of the CJC-1295/ipamorelin blend.
- Beck et al. IV ipamorelin after bowel surgery
International Journal of Colorectal Disease, 2014. Different route, population and outcome from wellness use.
- Francis et al. IGF-1 analogues and binding proteins
Journal of Molecular Endocrinology, 1992. Laboratory analogue research, not a muscle-building clinical trial.
- FDA: Compounding questions and answers
The distinction between compounded medications and FDA-approved drug products.
